

# Ben O'Leary

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2918484/publications.pdf>

Version: 2024-02-01

21  
papers

2,613  
citations

687363

13  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

4358  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2 <sup>+</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2022, 28, 3433-3442.	7.0	65
2	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 309-317.	6.3	60
3	Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. <i>Clinical Cancer Research</i> , 2020, 26, 608-622.	7.0	71
4	COVID-19: A Catalyst for Change for UK Clinical Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 462-465.	0.8	5
5	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. <i>Clinical Chemistry</i> , 2019, 65, 1405-1413.	3.2	53
6	ESR1 mutations in metastatic lobular breast cancer patients. <i>Npj Breast Cancer</i> , 2019, 5, 9.	5.2	26
7	Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1010-1010.	1.6	8
8	Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. <i>Nature Communications</i> , 2018, 9, 896.	12.8	305
9	Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. <i>Annals of Oncology</i> , 2018, 29, 145-153.	1.2	114
10	Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer. <i>Oncotarget</i> , 2018, 9, 12812-12824.	1.8	8
11	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. <i>Cancer Discovery</i> , 2018, 8, 1390-1403.	9.4	397
12	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. <i>Clinical Chemistry</i> , 2018, 64, 1626-1635.	3.2	46
13	Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1001-1001.	1.6	11
14	Predicting sensitivity to palbociclib with early circulating tumor DNA dynamics in the PALOMA-3 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1018-1018.	1.6	6
15	Treating cancer with selective CDK4/6 inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 417-430.	27.6	806
16	Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor <sup>+</sup> Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2961-2968.	1.6	573
17	Craniospinal irradiation with concomitant and adjuvant temozolomide—a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. <i>Journal of Neuro-Oncology</i> , 2016, 127, 295-302.	2.9	8
18	Abstract LB-069: ESR1 mutations in circulating tumour DNA predict outcome to endocrine treatment in patients with estrogen receptor positive advanced breast cancer; analysis of 521 patients in the SoFEA and PALOMA3 trials. , 2016, , .		1

#	ARTICLE	IF	CITATIONS
19	Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and <i>ESR1</i> mutations (mus) in circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2016, 34, 512-512.	1.6	17
20	Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer. PLoS ONE, 2016, 11, e0165023.	2.5	29
21	Recalibrating emergency care in the UK: pulling our weight. Lancet Oncology, The, 2015, 16, e195.	10.7	1